Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sensiblu is one of the leading pharmacy chains in Romania, offering a wide range of pharmaceutical products, health supplements, and dermo-cosmetics. Established in 1997, the company grew to become a dominant player in the Romanian retail healthcare market through its extensive network of pharmacies and a strong focus on customer loyalty programs. In 2018, Sensiblu and its parent group, A&D Pharma, were acquired by the Dr. Max Group, a major European pharmacy operator owned by Penta Investments. Following the acquisition, many Sensiblu locations have been rebranded to Dr. Max, although the Sensiblu brand remains recognized for its premium service and specialized product offerings. The company provides essential healthcare services, including prescription fulfillment and professional medical advice, to millions of customers across Romania.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sensiblu.